CUTL1, also known as CDP, Cut, or Cux-1, is a homeodomain transcriptional regulator known to be involved in development and cell cycle progression. Here we report that CUTL1 activity is associated with increased migration and invasiveness in numerous tumor cell lines, both in vitro and in vivo. Furthermore, we identify CUTL1 as a transcriptional target of transforming growth factor β and a mediator of its promigratory effects. CUTL1 activates a transcriptional program regulating genes involved in cell motility, invasion, and extracellular matrix composition. CUTL1 expression is significantly increased in high-grade carcinomas and is inversely correlated with survival in breast cancer. This suggests that CUTL1 plays a central role in coordinating a gene expression program associated with cell motility and tumor progression.
Introduction
CUTL1 has been demonstrated to be a phosphorylation target of several kinases that modulate its DNA binding affinity: phosphorylations by cyclin A-cdk1 and by PKC at various sites CUTL1, also known as CDP (CCAAT displacement protein), have been shown to inhibit DNA binding activity (Coqueret et Cut, or Cux-1, belongs to a family of homeobox transcription al., 1996; Santaguida et al., 2001) . No reports exist so far on factors involved in the regulation of cell growth and differentiathe transcriptional regulation of CUTL1 in mammalian cells. tion (Nepveu, 2001) . It is evolutionarily conserved and contains Studies in flies indicate that the Drosophila homolog of CUTL1, four DNA binding domains, three of which are known as Cut Cut, is a major determinant of cell type specification downrepeats and one as a Cut homeodomain (Harada et al., 1995) .
CUTL1 has been described as a transcriptional activator as stream of the notch pathway (Tavares et al., 2000) and may also interact with the wingless (Wg) signaling pathway (Micwell as a transcriptional repressor. Its activity has been associated with cellular proliferation and cell cycle progression (Van chelli et al., 1997) .
The role of CUTL1 in tumorigenesis and tumor progression Wijnen et al., 1996; Coqueret et al., 1998; Truscott et al., 2003) , as well as modulation of genes involved in terminal differentiaremains to be elucidated. Although initial databases on loss of heterozygosity studies suggested that CUTL1 might be a tion (van Gurp et al., 1999; Skalnik et al., 1991) . Knockout studies with the murine homolog, Cux-1, revealed reduced candidate tumor suppressor gene (Zeng et al., 1999) , a recent report suggests instead that CUTL1 could play a role in progrowth, retarded differentiation of the lung epithelia, hair follicle defects, reduced male fertility, and deficient T and B cell funcmoting breast cancer: Goulet et al. describe a tissue-specific CUTL1 isoform that appears to be strongly expressed in some tion (Ellis et al., 2001; Luong et al., 2002; Sinclair et al., 2001) . In contrast, mice transgenic for Cux-1 showed organomegaly breast tumors and, when overexpressed, inhibits tubule formation of breast cancer cells in vitro . and multiorgan hyperplasia (Ledford et al., 2002) .
Numerous signaling pathways have been implicated in the regulation of tumor progression and cell invasion. TGFβ is known to be a major modulator of tumor cell migration (Massague, 1998) , invasiveness (Seton-Rogers et al., 2004) , and epithelial-mesenchymal transition (EMT) (Grunert et al., 2003) . In addition to the canonical Smad-mediated signaling pathway, TGFβ also activates other pathways involving mitogen-activated protein kinases (MAPK), including JNKs and p38MAPK (Yu et al., 2002) .
We have identified CUTL1 in a high-throughput screen for modulators of cell motility using an RNA interference librarybased approach (O.E.P. and J.D., unpublished data). In this assay, CUTL1 was discovered as a potential positive regulator of cell motility. Based on these results, we aimed to characterize the role of CUTL1 in the control of cell migration, invasiveness, and tumor progression. Here we demonstrate that CUTL1 strongly promotes cell motility and invasiveness in a variety of cell systems in vitro and in vivo. In addition, we investigated the effects of tumor-related signaling pathways on the transcriptional activity of CUTL1. We could show that CUTL1 is a transcriptional target of TGFβ, thereby mediating promigratory effects of TGFβ. The important role of CUTL1 in promoting cell motility and invasiveness is underlined by the fact that CUTL1 expression is strongly associated with a less differentiated phenotype in breast and pancreatic carcinomas and with decreased patient survival in invasive breast cancer.
Results

Generation of cell lines stably expressing CUTL1 RNAi vector
CUTL1 was identified in a high throughput RNA interference screen for genes that influence cell motility. This screen utilized the Netherlands Cancer Institute RNA interference library, which targets 8,000 human genes (Berns et al., 2004 ), and will be described in detail elsewhere (O.E.P. and J.D., unpublished data). Briefly, three RNA interference vectors against each gene were cotransfected together with a GFP expression construct into highly motile carcinoma cells. One gene was analyzed per transfected well. After two days, fluorescent cells were identified and tracked by time-lapse video microscopy for a further day. Cells expressing CUTL1 RNAi vectors showed significantly decreased motility.
In order to study the biological role of endogenous CUTL1, ther studies. Expression differences of nuclear CUTL1 could C: Morphological appearance of subconfluent and confluent NIH3T3 conalso be confirmed by immunocytochemistry ( Figure 1B ). Intertrol and CUTL1 shRNA cells, as shown by phase-contrast microscopy. Bars estingly, diminished CUTL1 expression was associated with a represent 50 m.
strikingly altered cell morphology. CUTL1 RNAi clones were increased in cell size and appeared to be less spindle-shaped compared to control clones a with normal fibroblast-like phevarious aspects of migratory behavior. First, directed migration notype ( Figure 1C ). The increase in cell size was confirmed by into an artificial "wound" was measured in a confluent monovarious FACS-based assays, including forward scatter, fluoreslayer culture of NIH3T3 cells with or without endogenous cein diacetate staining, and FITC staining (data not shown).
CUTL1 expression (control versus CUTL1 RNAi). Control cells extensively migrated into the wound area within 8 hr, but this CUTL1 enhances migration and invasion To examine the effects of CUTL1 on cell motility and migration, was significantly reduced in CUTL1 RNAi cells (Figures 2A and  2B ). Similar results were also obtained by using two-chamber we employed three different tissue culture assays examining migration assays in which cells migrated through a membrane we performed video time-lapse microscopy and two-chamber migration assays on a variety of different cell lines after tranwith 8 m pores from serum-free medium toward 10% FCScontaining medium. In the CUTL1 RNAi clones, the proportion sient transfection of synthetic siRNA oligonucleotides targeting different regions of CUTL1 to the shRNA vector. First, we of migrated cells was significantly reduced ( Figure 2C ).
Knockdown of CUTL1 also slightly reduced cell proliferation, could demonstrate that with this transient approach, we could achieve a marked reduction of CUTL1 protein levels in all cell but to a much lesser extent than its effects on migration (see Supplemental Figure S1 ). To rule out a bias due to differences lines used (see Supplemental Figure S2 ). Various cell lines of different origin, such as fibrosarcoma (HT1080), glioblastoma in proliferation, we also tracked single cells by video time-lapse microscopy, whereby we could confirm that CUTL1 RNAi cells (U87-MG), and breast cancer (MDA-MB-231) cells all showed significantly reduced motility when endogenous CUTL1 was displayed significantly lower motility ( Figure 2D ). For representative time-lapse video, see Supplemental Videos. suppressed, as assayed by time-lapse microscopy ( Figure 2E ). This was also confirmed by two-chamber migration assays for To demonstrate that these observations are not specific for fibroblasts or for a single CUTL1 RNA interference sequence, a variety of cell lines of mesenchymal and epithelial origin, in-cluding PANC1 pancreatic carcinoma cells ( Figure 2F ). To demonstrate that the observed effect was not an off-target effect of one particular siRNA oligonucleotide, we confirmed that two different oligonucleotides targeting different regions of the CUTL1 mRNA were able to decrease CUTL1 expression paralleled by a decreased migration in HT1080 cells (see Supplemental Figure S3 ). Furthermore, the suppression of CUTL1 led to a marked actin reorganization and a decrease in focal adhesions and membrane protrusions associated with cell motility, as assayed by phalloidin staining, in both NIH3T3 fibroblasts and MDA-MB-231 epithelial cells ( Figure 2G and Supplemental Figure S4 ). The decreased number of focal adhesions in NIH3T3 cells was confirmed by a decrease in vinculin-positive adhesion sites (see Supplemental Figure S5 ). To examine whether CUTL1 also affects invasiveness involving movement through a three-dimensional matrix, we performed in vitro invasion assays with several invasive cell lines, including MDA-MB-231 breast cancer and PANC1 pancreatic cancer cells. Invasion through a membrane with 8 m pores coated with a 30 m layer of Matrigel consisting of extracellular matrix proteins was significantly reduced by over 30% in either cell line when endogenous CUTL1 was transiently suppressed by siRNA transfection ( Figure 2H ).
To confirm these results implicating CUTL1 in invasiveness in vivo, we generated stable CUTL1 knockdown clones by shRNA vector introduction into the invasive cell lines HT1080 fibrosarcoma, MDA-MB-436 breast carcinoma, and PANC1 pancreatic carcinoma, resulting in a significant reduction of CUTL1 expression in each cell line (Figures 3A and 3B and data not shown). Tail vein injection of two clones each with or without endogenous CUTL1 knockdown into nude mice resulted in a significant reduction of pulmonary metastatic colo- ways also affect CUTL1 transcription. CUTL1 mRNA induction by TGFβ appeared 4 hr after addition of TGFβ, suggesting that CUTL1 is not one of the early response genes of TGFβ ( Figure  4C ). To investigate the pathways acting downstream of TGFβ cells lacking Smad4 showed significantly lower CUTL1 protein in CUTL1 upregulation, we used clones of the mouse hepatolevels than wild-type cells ( Figure 4D ), as did MDA-MB-436 cyte cell line AML12 in which the expression of Smad4 had cells with transient Smad4 suppression (see Supplemental been stably suppressed by shRNA (A.R.R. and J.D., unpub- Figure S6 ) and PANC1 cells (data not shown), indicating lished data) as well as MDA-MB-436 breast cancer cells with that Smad4-dependent signaling is involved in the transcriptional regulation of CUTL1. In addition, coincubation with the or without transient suppression of Smad4 by siRNA. AML12 p38MAPK inhibitor SB202190 resulted in additional downregulation of both basal and TGFβ-induced CUTL1 levels ( Figure  4D and Supplemental Figure S6 ), indicating that p38MAPK-dependent signaling, known to be an additional effector pathway downstream of TGFβ, also plays a role in modulating CUTL1 levels.
CUTL1 is required for TGFβ effects on migration
To test the biological significance of the TGFβ-induced upregulation of CUTL1, we examined the influence of CUTL1 on migration in the presence or absence of TGFβ. Addition of TGFβ significantly increased the migration of NIH3T3 control cells, paralleled by an increase in CUTL1 levels. In contrast, in stable CUTL1 RNAi NIH 3T3 cells, the effect of TGFβ on the basal migration rate was absent ( Figure 5A ). These results were confirmed by two-chamber migration assays ( Figure 5B ) and wound healing assays ( Figure 5C ). Furthermore, transient transfection of HT1080 fibrosarcoma cells with CUTL1 siRNA confirmed that both basal and TGFβ-induced migration strongly correlate with the level of CUTL1 expression ( Figure 5D ), which was also observed in MDA-MB-231 breast cancer cells (data not shown). Based on these data, it appears likely that CUTL1 expression is required for TGFβ to exert its promigratory effects. To examine whether CUTL1 mediates TGFβ-induced epithelial-mesenchymal transition (EMT), thereby enhancing cell migration, we used EpH4 and Ha-Ras-transformed EpH4 (EpRas) mammary epithelial cells before and after TGFβ-induced EMT (EpRasXT cells), a cell system which has been described as a model system for EMT (Jechlinger et al., 2003) . However, despite decreasing cell motility as confirmed by Boyden chamber assays, CUTL1 knockdown did not in any way alter the expression levels of any of the marker proteins associated with EMT, such as E cadherin, vimentin, or cytokeratin 8/18 (data not shown). Therefore, CUTL1 seems to mediate promigratory effects of TGFβ independently of EMT and does not appear to play a role in the regulation of EMT.
Transcriptional effects of CUTL1 knockdown
To determine the transcriptional program regulated by CUTL1 that might underlie the differences seen in cell motility and invasion, we performed Affymetrix microarray gene expression Using highly stringent significance criteria, we generated performed using mCUTL1 specific primers, and Western blot was perlists containing genes which were more highly expressed in (Table 1) .
of SMAD4 by shRNA. Anti-CDP antibody (Santa Cruz) was used. Cells were Many of these have previously been described as modulators grown in 10% fetal calf serum.
of cell invasion in various tumor cell models (see Discussion). The group of downregulated genes ( Table 2) consists mainly of genes associated with inflammatory reaction, acute-phase response, and chemotaxis, as well as genes encoding secreted extracellular matrix proteins. We could confirm the microarray data for the vast majority of the genes tested, both on RNA (see Supplemental Figure S7 ) and protein levels (see Supplemental Figure S8 ) as well as on promoter level for selected genes (see Supplemental Figure S9 ). To demonstrate that the identified target genes are not specific for NIH3T3, we performed additional experiments using real-time PCR after transient knockdown of CUTL1 in various cancer cell lines. We could confirm that several CUTL1 target genes identified by the microarray experiments, such as WNT5A, were also regulated by CUTL1 in fibrosarcoma and breast and pancreatic cancer cells (see Supplemental Figure S10 ).
Taken together, these microarray results suggest that CUTL1 predominantly regulates genes involved in migration, invasion, adhesion, and modulation of the extracellular matrix, indicating that it might be involved in the control of cell motility in vitro and invasiveness in tumors.
CUTL1 expression is increased in high-grade breast and pancreatic cancers
As reduction in CUTL1 expression leads to reduced motility and invasiveness of cell lines from several tissue origins both in vitro and in vivo, we sought to elucidate the physiological relevance of CUTL1 in tumor progression and metastasis by studying CUTL1 expression in 138 patients with invasive ductal carcinoma of the breast where full histopathological data and active clinical followup up to 22 years were available. This cohort was analyzed for known prognostic markers (estrogen receptor, progesterone receptor, tumor size, lymph node status, histological grade) and showed trends in overall and relapsefree survival in keeping with the expected outcome. For detailed patient characteristics, see Supplemental Table S1 . In situ hybridization on multiple tissue core arrays showed CUTL1 expression in more than half of the tumors. Interestingly, poorly differentiated high-grade (G3) breast carcinomas expressed significantly more CUTL1 than well-differentiated low-grade (G1) tumors ( Figures 6A and 6B ). This correlation was confirmed in an independent series of 35 breast cancer tissues by immunohistochemistry, demonstrating higher expression of CUTL1 protein in G2 and G3 tumors as compared to G1 tumors ( Figures 6C and 6D) . Furthermore, in patients with highgrade (G3) tumors, CUTL1 expression, as assessed by ISH, inversely correlated with relapse-free survival ( Figure 6E ) and overall survival (see Supplemental Figure S11 ) as a prognostic marker. To further corroborate our data with another epithelial CUTL1 expression (lower panel). Experiments were performed in serum con-B: Quantification of the two-chamber migration assay of stable NIH3T3 taining medium. cancer, we performed immunohistochemistry with a multiple ings, we examined the role of CUTL1 in the regulation of cell motility and invasiveness. In summary, we found that depletion tissue array containing 25 pancreatic cancer tissues with defined grade. These pancreatic cancer tissues also showed a of CUTL1 from various cell types results in reduction in cell motility and invasiveness, both in vitro and in vivo. CUTL1 is stronger CUTL1 protein staining in high histological grade (G2/3) tumors compared to low grade (G1) tumors (see Supplerequired for the expression of a number of cell surface and other proteins involved in the control of cell adhesion and mimental Figures S12 and S13 ). These data on RNA and protein levels strongly indicate that elevated levels of CUTL1 expresgration. In addition, TGFβ treatment increases CUTL1 expression, which is required for short-term effects of TGFβ on cell sion may play an important role in enhancing invasiveness and tumor progression in breast and pancreatic cancer.
motility. CUTL1 expression is found to correlate with increased histological grade and poor prognosis in breast cancer. Our hypothesis, based on the RNAi high-throughput screen, Discussion that CUTL1 plays a role in the regulation of cell motility could be confirmed experimentally by migration and invasion assays The ability to migrate and invade through the basement memin a number of systems in vitro and in vivo. CUTL1 expression brane into surrounding tissues, blood, and lymphatic vessels is required for efficient migration of both epithelial and mesis one of the essential hallmarks of cancer and a prerequisite enchymal cells on a two-dimensional surface in vitro and for for local tumor progression and metastatic spread. In an RNAioptimal invasion through a three-dimensional gel of extracellulibrary-based high-throughput screen for regulators of cell motility (O.E.P. and J.D., unpublished data), we identified CUTL1 lar matrix. In addition, reduction in CUTL1 expression severely impaired the ability of tumor cells to form lung colonies in an as a potential modulator of cell migration. Based on these find- (p200), from which a shorter, more active form (p110) is generated by proteolytic processing. A several crucial aspects of the metastatic process, such as the ability of single cancer cells to adhere, survive, and proliferate still shorter version of CUTL1 (p75) is made from an mRNA transcribed from an alternative initiation site within intron 20, in a different organ context. Some other prerequisites of metastasis, such as the ability of cells to enter the circulation through but this would not be recognized by the in situ hybridization probe used here . CUTL1 p75 has more a basement membrane, however, are not addressed by the pulmonary colonization assay. Overall, we suggest that high stable DNA binding activity and has been shown to disrupt tubule formation in collagen by T47D breast carcinoma cells levels of CUTL1 expression are associated with the increased motility typical of invasive carcinoma cells, in contrast to the when overexpressed. Recently, cathepsin cysteine proteases have been described normally relatively nonmotile untransformed epithelial cells.
Since TGFβ is known to be a major modulator of cell migraas being important effectors of invasive growth and angiogenesis during multistage tumorigenesis. Several different catheption and invasion (Massague, 1998; Lehmann et al., 2000) , we tested its effect on CUTL1 expression, finding that CUTL1 is sins were found to be expressed at increased levels in various cell types involved in tumor progression in the RIP-Tag2 mouse transcriptionally induced following TGFβ treatment. We therefore propose that CUTL1 might be a significant new pathway model of pancreatic islet cell carcinogenesis, including cathepsin L, which was expressed exclusively in the tumor cells through which TGFβ exerts its promigratory and proinvasive effects. These effects of TGFβ fall into two classes: short-term (Joyce et al., 2004 ). An isoform of cathepsin L lacking a signal peptide localizes to the nucleus in S phase and has been rechanges, occurring in a few hours (Seton-Rogers et al., 2004) , and long-term changes, requiring altered differentiation of the ported recently to process CUTL1 p200 to the more transcriptionally active p110 form (Goulet et al., 2004) . It is possible that cell through epithelial-mesenchymal transition (Grunert et al., 2003) . CUTL1 does not appear to play a role in the regulation increased cathepsin L expression in tumor cells synergizes with elevated CUTL1 levels by promoting its posttranslational of EMT, but is required for the short-term effects of TGFβ on cell motility, involving both SMAD4-dependent and p38 MAPKprocessing and activation, leading to elevated expression of CUTL1 target genes involved in tumor cell invasion of surdependent pathways. Initial analysis of the murine CUTL1 promoter suggests the presence of a putative SMAD binding site rounding tissue. We investigated the identity of genes whose expression is within 2 kilobases upstream of the transcriptional start site. However, since this site is not consistently conserved among regulated by CUTL1 by the combined use of RNA interference technology and microarray expression profiling. Transcriptional mammalian species, its physiological significance remains to be elucidated. Further investigation will be required to deterprofiling after suppression of endogenous CUTL1 expression by shRNA avoids potential biases introduced by overexpresmine the exact mechanism whereby CUTL1 gene expression is controlled by TGFβ. sion techniques, thus probably providing a more physiologically relevant global expression profile. The gene expression By using multiple tissue core arrays, we could demonstrate the pathophysiological significance of CUTL1 expression in profile observed is likely to be specific for knockdown of CUTL1: we did not observe significant upregulation of inbreast and pancreatic cancer. The increased expression of CUTL1 in high-grade breast and pancreatic cancers and its terferon-response genes (Bridge et al., 2003) , described as nonspecific side effects induced by some siRNAs, and we had inverse correlation with overall and relapse-free survival of patients with breast cancer suggests that CUTL1 transcriptional no indication of major off-target effects of the RNA sequence used for generating the stable RNAi clones. While these seactivity has a major impact on tumor progression. The probe used for in situ hybridization will recognize mRNA encoding quences did not have any perfect matches other than CUTL1 Figure 6 . CUTL1 is highly expressed in high-grade breast cancer and correlates with grading and survival
A:
In situ hybridization with hCUTL1 probe of 1 normal breast tissue and 3 representative breast cancer tissues with different histopathological grades and increasing levels of CUTL1 RNA. On the right, hCUTL1-positive areas are revealed as autoradiographic silver grains in dark-field images; on the left, the same specimens are shown by Giemsa staining. Bars represent 200 m. B: CUTL1 mRNA expression levels in grade 1 (G1) and grade 3 (G3) breast cancers. CUTL1 expression was scored as negative (0), or positive (three levels: +, ++, +++). Proportion of tumors with the respective score out of 138 examined tissues is given. Significance was calculated by nonparametric permutation testing. C: Immunohistochemistry using the rabbit anti-GST-CUTL antibody of 1 normal breast tissue and 3 representative breast cancer tissues with different histopathological grades and increasing protein levels of CUTL1. Bars represent 100 m. D: CUTL1 protein expression levels in grade 1 (G1) and grade 2/3 (G2/3) breast cancers. CUTL1 expression was scored as negative (0) in the relevant mammalian genomes, genes showing partial plicated in the progression of several tumor types, including breast cancer (Friedrichs et al., 1995; Guo and Giancotti, matches (13-15/19 ) to the RNAi sequence by BLAST search 2004). Reduced α6 integrin expression could lead to reduced did not show any suppression of expression in the microarray adhesiveness on laminin extracellular matrix and hence reexperiments.
duced invasiveness. In addition, among the genes negatively Many of the CUTL1 upregulated target genes identified by regulated by CUTL1 were several proteoglycans, downregulathe microarray analysis have previously been described as tion of which has been associated with poor outcome in invamodulators of cell invasion in various tumor cell models: sive breast cancer (Troup et al., 2003) . among others, pleiotrophin (PTN), a secreted heparin binding
The data presented here demonstrate that the transcription growth factor, induces growth and metastasis in mesenchymal factor CUTL1 plays a critical role in establishing a pattern of cells (Chauhan et al., 1993) and is rate-limiting for glioblastoma gene expression that favors cancer cell motility and invasive growth (Powers et al., 2002) . WNT5A, a member of the wingbehavior. CUTL1 expression is induced by TGFβ and is reless gene family, has been associated with motility and invaquired for TGFβ promotion of cell motility. If the technical probsion of metastatic melanoma (Weeraratna et al., 2002) . ALlems inherent in targeting transcription factors could be over-CAM, a member of the immunoglobulin superfamily, enhances come, CUTL1 could represent a novel target for the blocking growth and migration (van Kempen et al., 2000) . S100A10
of tumor invasion. functions as a plasminogen receptor and has been shown to Experimental procedures enhance invasiveness of colorectal cancer cells (Zhang et al., 2004) . Perhaps most significantly, α6 integrin (ITGA6) is exPlasmids and siRNA pressed considerably more strongly in the presence of CUTL1:
Myc-tagged full-length human CUTL1 in pMX, as well as CUTL1 nt 831-1336, in pXJ42 were kind gifts from A. Nepveu. The shRNA for mouse and this integrin, particularly in combination with β4, has been im-human CUTL1 (5#-AAGAAGAACACTCCAGAGGATTT-3#) was cloned as (http://www.genmapp.org/MAPPFinder.html). Significantly regulated genes hairpin oligonucleotide into pSuper.retro.puro (Oligoengine, Seattle, WA) acare presented with the ratio between the mean expression values of two cording to the manufacturer's instructions, and stable clones were obtained CUTL1 expressing clones and two CUTL1 shRNA knockdown clones each after selection with puromycin. The shRNA for mouse SMAD4 was cloned in duplicate experiments (4 data points per group). into pSuper (A.R.R., unpublished data) and cotransfected with pBabe.puro for puromycin selection. Control clones were obtained after transfecting the RT-PCR empty vectors.
Reverse transcription was performed using the Superscript first strand synThe reporter plasmids for WNT5A, DAB2, and PTN were generated by thesis kit (Invitrogen). PCR was performed for 30 cycles. Quantitative real-PCR amplification of the 2 kb upstream the transcriptional start site and time PCR analyses using the comparative C T method were performed on cloning of the 2 kb DNA fragments into the KpnI/BglII sites of pGL3-an ABI PRISM 7700 Sequence Detector System using the SYBR Green Enhancer (Promega, Madison, WI). The DNA polymerase α-pGL3-basic-Luc PCR Master Mix kit (Perkin Elmer, Applied Biosystems, Wellesley, MA, USA) (−1517/+45) was a kind gift from A. Nepveu (Truscott et al., 2003) , and the according to the manufacturer's instructions. Following initial incubation at CD34 454-SCL-pXSH-Luc construct was a kind gift from D. Krause (Krause 50°C for 2 min and 10 min at 95°C, amplification was performed for 40 et al., 1997).
cycles at 95°C for 15 s and 60°C for 1 min. Specific primer pairs were For transient transfection of CUTL1 siRNA, the following sense sedetermined with the PrimerExpress program (Applied Biosystems). The huquences were used (purchased from Ambion, Austin, TX): hCUTL1/I 5#-man cyclophilin A gene (RefSeq ID NM_021130) was used as the internal GGAACAGAAGUUACAGAAUtt-3#, hCUTL1/II 5#-GGAAGCUGAAGCAGCU standard. Primer sequences are available on request. UUCtt-3#, mCUTL1: 5#-GGUUCUGGAAUAACUCUUUtt-3#. For transient transfection of hSMAD4 siRNA, the following sense sequence was used:
Western blotting hSMAD4 5#-GGUGGAGAGAGUGAAACAUtt-3#. 140 pmole siRNA/well was 5 × 10 5 cells were lysed in HEPES buffer containing 1% Triton X-100, sonitransfected using Effectene or Transmessenger (Qiagen, Hilden, Germany) cated, size-fractionated by SDS-PAGE on precast gels (NuPAGE, Invitroas transfection agent in 6-well plates. As negative control, the Silencer gen), and blotted onto PVDF membranes (Millipore, Watford, UK). The folNegative Control siRNA from Ambion was used. In the motility assays, cells lowing antibodies were used for immunodetection: rabbit anti-CDP (Santa were transfected with siRNA twice, with an interval of 24 hr. Three hours Cruz, Santa Cruz, CA), our own rabbit anti-CUTL1 (antigen: GST-hCUTL1 after the second transfection, the cells were split sparsely for migration, and nt2551-3451), goat anti-actin (Santa Cruz), rabbit anti-DAB2 (Santa Cruz), another three hours later, the tracking experiment was started for 24 hr.
mouse anti-N-cadherin (Zymed, San Francisco, CA), rabbit anti-lumican (kind gift of T. Ishiwata, Tokyo), mouse anti-ALCAM (Antigenix America,
Materials and cell lines
Huntington Station, NY), rabbit anti-mouse SDF1A/CXCL12 (Peprotech, Puromycin (2.5 g/ml) was obtained from Sigma. The p38MAPK inhibitor London, UK), mouse Annexin II light chain/S100A10 (BD Transduction SB202190 (10 M) was from Calbiochem, and rhTGFβ (10 ng/ml) was from Laboratories), goat anti-SEMA3A (Santa Cruz), rabbit anti-IL1A (Abcam). R&D systems. ALK4/5/7 inhibitor SB431542 was a kind gift from C. Hill, Following peroxidase-coupled secondary antiserum (Amersham Pharmacia, London. All cell lines were obtained from ATCC.
Little Chalfont, UK), blots were detected by ECL chemiluminescence (Amersham).
Multiple tissue core arrays
The human breast carcinoma tissues were obtained from the tissue bank Luciferase reporter assays at Cancer Research UK Breast Pathology Laboratory at Guy's Hospital, Cells were transiently transfected using GeneJuice (Merck Biosciences, London. All human tissues were used with approval of the local research Nottingham, UK) according to the manufacturer's instructions, and harethics committee. Multiple tissue core arrays were produced from represenvested 24 hr after transfection. Because the internal control plasmid is itself tative tumor areas from donor blocks of cases from the Guy's unit and often repressed by CDP/Cux, as a control for transfection efficiency, the validated as described for in situ hybridization (Gillett et al., 2000) . Each purified β-galactosidase protein (Sigma) was included in the transfection case had been previously assessed for tumor size, lymph node status, mix, as previously described (Truscott et al., 2003; Howcroft et al., 1997) . estrogen, and progesterone receptor status. For detailed characteristics of The luciferase assays were performed using the Luciferase Assay System the cases used see, Supplemental Table S1 . Grading was determined by (Promega, Madison, WI) , and β-galactosidase activity was detected using using the modified Bloom & Richardson system (Elston and Ellis, 1991) .
2-Nitrophenyl β-D-galactopyranoside (ONPG, Sigma, Poole, UK) in subAs independent data sets for immunohistochemical studies, commercially strate buffer (1 mM MgCl 2 , 1 mg/ml ONPG, 75 mM sodium phosphate available breast and pancreatic cancer tissue core arrays (Petagen Inc., buffer [pH 7.4 ], 60 mM β-mercaptoethanol) at 420 nm. Seoul, Korea) were used. The breast array contained 4 nonneoplastic breast tissues and 50 carcinoma tissues, among them 35 with defined histological Wound healing assays grade (Bloom & Richardson system). The pancreatic array contained 4 nonAn artificial "wound" was created using a 10 l pipette tip on confluent cell neoplastic pancreas tissues and 33 carcinoma tissues, among them 25 with monolayers in 6-well culture plates in serum-containing medium. Phodefined histological grade which were used for the correlation with CUTL tographs were taken at 0 and 8 hr. Quantitative analysis of the wound cloexpression. The statistical analyses were calculated using the statistical sure was calculated by counting the number of cells per 10 5 m 2 wound package S-Plus.
area at 8 hr.
Flow cytometry Two-chamber migration and invasion assays FACS analysis was performed as described previously (Michl et al., 2003) .
Cell invasion was determined by using the modified two-chamber migration For fluorescein diacetate staining (Elliott et al., 2003) , cells were resusassay (8 m pore size, BD Biosciences) or invasion assay (membrane pended in 1 ml PBS at 10 6 per ml, and 10 l of fluorescein diacetate (1 g/ coated with a layer of Matrigel extracellular matrix proteins) according to ml) was added to the cells for 10 min. For FITC staining (Crissman and the manufacturer's instructions. 2.5 × 10 4 cells were seeded in serum-free Steinkamp, 1973) , cells were resuspended in 1 ml PBS containing 5 l FITC medium into the upper chamber and migrated/invaded toward 10% FCS (1 g/ml), 20 l propidium iodide (2 mg/ml), and 50 l RNase (100 g/ml)
as a chemoattractant in the lower chamber for 6 hr (HT1080 cells) or 18 hr for 30 min.
(all other cell lines). Cells in the upper chamber were carefully removed using cotton buds and cells at the bottom of the membrane were fixed and Microarray analysis stained with crystal violet 0.2%/methanol 20%. Quantification was perExperiments using Affymetrix GeneChip Mouse Genome 430A 2.0 Array formed by counting the stained cells. oligonucleotide arrays were performed following the manufacturer's recommendation (http://www.affymetrix.com/support/technical/manual/expression_ Video time-lapse microscopy manual.affx). A complete description of all procedures and statistical analyTime-lapse imaging of migrating cells was performed on an inverted Zeiss sis is available in the MIAME checklist file in the Supplemental Data. Annotation and classification of the genes was performed using MAPPFinder Axiovert 135TV microscope (X-Y-Z motorized stage/piezo Z control; Zeiss, Jena, Germany) over 24 hr in serum-containing medium at 37°C/10% CO 2 . the statistical analysis. This work was supported by core funding from Cancer Research UK and by a research fellowship from the Deutsche Images were obtained with a Hamamatsu Orca ER firewire CCD camera Forschungsgemeinschaft (DFG) to P.M. every 7 or 20 min, and analyzed using image analysis software (AQM Advance6 and Tracker, Kinetic Imaging Ltd, Bromborough, UK). Migration of each cell was analyzed by measuring the distance traveled by a cell nucleus over the 24 hr time period. Statistical analysis was performed using the
